Thursday, June 13, 2024 Current Time : 3:8 in Tehran
Created Date : Tuesday, June 30, 2020   Update Date : Monday, October 2, 2023    Visit : 1828



Dr. Fariba Ahmadizar


Department of Epidemiology

Erasmus University Medical Center


E-mail Address:

Phone: +31 10 70 44820

Address: Erasmus MC, University Medical Center Rotterdam, Office Na-2710, PO Box 2040, 3000 CA Rotterdam, the Netherlands




Prof. Fariba Ahmadizar has been working as a postdoctoral scientist in the Department of Epidemiology, Erasmus Medical Center (MC), the Netherlands since 2017. Dr. Ahmadizar obtained her Doctor of Pharmacy (Pharm.D.) from Shahid Beheshti University of Medical Sciences, Iran, and did her M.Sc. in Epidemiology and Ph.D. in Pharmacoepidemiology both at Utrecht University. Doing her Ph.D., she studied risk factors and medications used in children with chronic disorders including asthma, allergy, and type 1 diabetes. However, her research now focuses on Precision Medicine to study the role of biomarkers, including omics data either in response to medications (Molecular Pharmacoepidemiology) or in the development of disorders (Clinical Epidemiology). She has strong knowledge of epidemiological study design, methods, statistics, and programming. Moreover, she has academic collaboration with researchers from Harvard University, Imperial College London, Diabetes Centers in Lund University Sweden and Denmark, and National Cancer Institute/Division of Cancer Epidemiology and Genetics in the United States. During her scientific training at Erasmus MC, she has been fortunate enough to have served as a lecturer/teaching assistant for courses of Pharmacoepidemiology, Molecular Pharmacoepidemiology as well as Diabetes Epidemiology at the Netherlands Institute for Health Sciences (NIHES).

In addition, Dr. Ahmadizar is an active member of the European Association of the Study of Diabetes (EASD) and the International Society for Pharmacoepidemiology (ISPE). Being actively engaged with editorial tasks, Dr. Ahmadizar is also one of the potential reviewers of European Journal of Preventive Cardiology (EJPC) and Lancet Endocrinology and JAMA.


Research Priorities:

Molecular Pharmacoepidemiology


Number and Duration of Previous Visits to SUMS:

3 times, 15 days in total